Highlights The Medicines Company

Equities

MDCO

US5846881051

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.14%	-0.05%

2020	The Medicines Company Announces Board Changes	CI
2020	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Novartis AG completed the acquisition of The Medicines Company.	20-01-02	CI
Novartis takes on Sanofi, Amgen with $9.7 billion takeover of heart drug maker	19-11-25	RE
Novartis AG entered into definitive agreement to acquire The Medicines Company for $6.8 billion.	19-11-23	CI
Novartis Reportedly Holds Talks to Acquire Medicines Co	19-11-19	CI
Medicines : Novartis eyes Medicines Co to boost cardio franchise - report	19-11-19	RE
The Medicines Company Announces ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing	19-11-16	CI
The Medicines Company Announces Detailed Results from the ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies of Inclisiran	19-11-06	CI
The Medicines Company Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-10-30	CI
The Medicines Company Announces Positive Topline Results for Orion-10 Phase 3 Study of Inclisiran in ASCVD Patients	19-09-25	CI
The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients	19-09-25	CI
The Medicines Company Presents Results from ORION-11	19-09-02	CI
The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran	19-08-26	CI
The Medicines Company Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-07-24	CI
The Medicines Company Updates Clinical Development Program	19-07-24	CI
The Medicines Company Intends To Seek Acquisitions	19-06-26	CI
Medicines Company Intends To Seek Acquisitions	19-06-25	CI
The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress	19-05-27	CI
The Medicines Company Announces Interim Results from the Ongoing Orion-3 Open-Label Extension Study	19-05-18	CI
The Medicines Company Presents Interim Results on Long-Term Safety and Efficacy of Inclisiran from the Ongoing ORION-3 Study During a Late-Breaking Clinical Trial Session at the National Lipid Association Scientific Sessions in Miami	19-04-25	CI
The Medicines Company Reports Earnings Results for the First Quarter Ended March 31, 2019	19-04-25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights The Medicines Company

Equities

MDCO

US5846881051

Highlights

Filters